Nitrogen, Other Than Nitro Or Nitroso, Bonded Directly To The 6-position Of A Purine Ring System (e.g., Adenosine, Etc.) Patents (Class 536/27.6)
Additional nitrogen bonded directly to the 2-position of the purine ring system (Class 536/27.61)
Nitrogen, chalcogen, or additional carbon bonded directly to the 6-position nitrogen (e.g., 6-position nitrogen is substituted, etc.) (Class 536/27.62)
Chalcogen, halogen, or benzene bonded directly to carbon of the purine ring system (e.g., isoguanosine, 2-fluoroadenosine, etc.) (Class 536/27.7)
  • Methods and compositions for treating inflammatory response
    Patent number: 6232297
    Abstract: Compounds and methods are provided to treat inflammatory conditions with certain A2A adenosine receptor antagonists.
    Type: Grant
    Filed: June 15, 1999
    Date of Patent: May 15, 2001
    Assignee: University of Virginia Patent Foundation
    Inventors: Joel M. Linden, Gail W. Sullivan, Ian J. Sarembock, Timothy MacDonald, Mark Okusa
  • Pharmaceutical therapy for congestive heart failure
    Patent number: 6221851
    Abstract: The present invention is directed to reduce elevated levels of tumor necrosis factor-alpha (TNF-&agr;) found in a failing heart. The present invention is directed to a composition and method of regulating TNF-&agr; expression in myocardial tissue by treating the myocardial tissue with biological equivalents of endogenous adenosine. A composition and method of using the composition to treat patients with damaged myocardial tissue is provided which increases the cellular availability of adenosine with a resulting decrease of TNF-&agr; levels in the heart. The present invention provides a novel pharmacological intervention program in failing mammalian hearts, and more particularly provides a cardioprotective treatment to patients with congestive heart failure.
    Type: Grant
    Filed: December 7, 1999
    Date of Patent: April 24, 2001
    Inventor: Arthur M. Feldman
  • C-pyrazole 2A A receptor agonists
    Patent number: 6214807
    Abstract: 2-adenosine C-pyrazole compositions having the following formula: and methods for using the compositions as A2A receptor agonists to stimulate mammalian coronary vasodilatation for therapeutic purposes and for purposes of imaging the heart.
    Type: Grant
    Filed: June 22, 1999
    Date of Patent: April 10, 2001
    Assignee: CV Therapeutics, Inc.
    Inventors: Jeff A. Zablocki, Venkata P. Palle, Elfatih O. Elzein
  • Procedure to block the replication of reverse transcriptase dependent viruses by the use of inhibitors of deoxynucleotides synthesis
    Patent number: 6194390
    Abstract: A method for inhibiting replication of reverse transcriptase dependent virus in plant or animal cells, comprising the step of administering to said cells a compound that depletes the intracellular pool of deoxyribonucleoside phosphate in an amount effective to inhibit replication of said virus. Hydroxyurea is one such suitable compound. Also disclosed is a method for producing incomplete reverse-transcriptase dependent viral DNA, by administering a deoxyribonucleoside phosphate-depleting drug to cells infected with such a virus.
    Type: Grant
    Filed: February 3, 2000
    Date of Patent: February 27, 2001
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Franco Lori, Andrea Cara, Wen-Yi Gao, Robert C. Gallo
  • Nucleoside derivatives, and their use in oligonucleotide synthesis
    Patent number: 6187914
    Abstract: The invention relates to nucleoside derivatives bearing electrolabile protector groupings and their use in an oligonucleotide synthesis method comprising at least one step of electronic deprotection.
    Type: Grant
    Filed: December 3, 1998
    Date of Patent: February 13, 2001
    Assignee: Cis Bio International
    Inventors: Robert Teoule, André Roget, Thierry Livache
  • Tumor imaging agents, methods and kits
    Patent number: 6187286
    Abstract: The invention provides tumor imaging agents comprising a radionuclide in association with a nucleotide polyphosphate targeting molecule. Methods for using the tumor imaging agents and kits containing the tumor imaging agents or components suitable for production of the tumor imaging agents are also provided.
    Type: Grant
    Filed: May 1, 1997
    Date of Patent: February 13, 2001
    Assignee: The General Hospital Corporation
    Inventors: David R. Elmaleh, John W. Babich
  • Aminooxy-modified oligonucleotides and methods for making same
    Patent number: 6172209
    Abstract: Oligonucleotides and other macromolecules are provided which have increased nuclease resistance, substituent groups (such as 2′-aminooxy groups) for increasing binding affinity to complementary strand, and subsequences of 2′-deoxy-erythro-pentofuranosyl nucleotides that activate RNase H. Such oligonucleotides and macromolecules are useful for diagnostics and other research purposes, for modulating the expression of a protein in organisms, and for the diagnosis, detection and treatment of other conditions susceptible to oligonucleotide therapeutics.
    Type: Grant
    Filed: August 7, 1998
    Date of Patent: January 9, 2001
    Assignee: ISIS Pharmaceuticals Inc.
    Inventors: Muthiah Manoharan, Phillip Dan Cook, Thazha P. Prakash, Andrew M. Kawasaki